Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 2 de 2
1.
CNS Neurosci Ther ; 27 Suppl 1: 20-24, 2021 03.
Article En | MEDLINE | ID: mdl-33555615

OBJECTIVES: To develop a local consensus to guide medical practitioners and psychiatrists on the use of bupropion in different psychiatric conditions in Hong Kong. METHODS: By utilizing the modified Delphi technique, a group of 10 local physicians with extensive experience in the management of major depressive disorder (MDD) developed and voted (using an anonymous, electronic voting system) on the practicality of recommendation of a set of consensus statements on the clinical use and understanding of bupropion in Hong Kong. RESULTS: There was a very high degree of agreement among the panelists on the 11 finalized consensus statements. CONCLUSIONS: The present consensus statements are developed as general recommendations for medical practitioners and psychiatrists to be practically referred to in clinical settings.


Antidepressive Agents, Second-Generation/therapeutic use , Bupropion/therapeutic use , Consensus , Delphi Technique , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/epidemiology , Hong Kong/epidemiology , Humans
2.
CNS Neurosci Ther ; 27 Suppl 1: 12-19, 2021 03.
Article En | MEDLINE | ID: mdl-33555616

Recent research on second-generation long-acting injectable antipsychotics (LAI SGAs) has proven its effectiveness in minimizing medication nonadherence problem and reducing relapses. Administered by medical professionals, making quick detection of nonadherence possible, long-acting injectable antipsychotics (LAIs) facilitate immediate intervention and recovery process, and thus are favored by psychiatrists. Despite a higher initial cost with LAIs, the subsequent schizophrenia-related health costs for hospitalizations and outpatients are greatly reduced. With reference to guidelines published by psychiatric associations around the globe, this article looks at scenarios in Hong Kong on the management of severe mentally ill patients with regard to the use of a host of psychosocial interventions as well as LAI SGAs as a preferable treatment. In particular, it examines the benefits of using LAI SGAs for Hong Kong patients who demonstrated high nonadherence treatment rates due to their social environment. It assesses the rationale behind the early usages of LAI SGAs, which help to provide better recovery outcomes for patients.


Antipsychotic Agents/therapeutic use , Expert Testimony/standards , Schizophrenia/drug therapy , Schizophrenia/epidemiology , Schizophrenic Psychology , Treatment Adherence and Compliance/psychology , Expert Testimony/methods , Hong Kong/epidemiology , Humans , Treatment Outcome
...